The aim of this review is to update readers on the growing impact of a molecular approach (CRD) to the diagnosis and treatment of children with respiratory allergies
A large panel of highly purified natural or recombinant species-specific and cross-reacting allergenic molecules is now available for clinical purposes. Species-specific molecules allow identifying specific sensitization toward a given allergenic source. Cross-reacting molecules allow interpreting polysensitization patterns that cannot be detailed using routine skin prick tests or specific IgE tests based on allergenic extracts. These molecular tools are transforming and improving the interpretation of clinical and laboratory tests used to define patients’ IgE-sensitization profile.
The accurate dissection of the IgE repertoire offers new possibilities in the diagnosis, prophylaxis and treatment of pediatric allergic rhinoconjunctivitis and asthma.
aDepartment of Experimental Medicine, Istituto Giannina Gaslini, Genova
bDepartment of Internal Medicine, Allergy and Respiratory Diseases, University of Genoa, Genoa, Italy
cResearch Centre in Respiratory Medicine, Catholic University, Cordoba, Argentina
dDepartment of Pediatric Pneumology and Immunology, Charité University Medical Centre, Berlin, Germany
Correspondence to Giovanni Melioli, MD, Department of Experimental Medicine, Istituto Giannina Gaslini, Via Gerolamo Gaslini 5, Genova 16147, Italy. Tel: +39 010 563 6557; fax: +39 010 399 4168; e-mail: email@example.com